Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial

Authors:

Abstract
No abstract available
Funding Information
  • Abbott Laboratories
  • Kowa Company
  • Bayer
  • Amgen
  • British Heart Foundation (RE/18/6/34217)
  • Novartis
  • Bristol-Myers Squibb
  • University of Glasgow
  • Sanofi
  • Eli Lilly and Company
  • Novo Nordisk
  • Boehringer Ingelheim
  • Merck Sharp and Dohme United Kingdom
  • AstraZeneca
  • Pfizer